方法：选取2011-02/2015-01就诊于我院及161医院眼科的中青年睑板腺功能障碍所致干眼症阴虚燥热证患者74例148眼，依据随机平均原则分为研究组和对照组，每组各37例74眼，对照组给予人工泪液等常规西医治疗，研究组在同对照组治疗的基础上加用自拟二冬玉竹汤治疗，评定治疗效果并记录治疗前后SchirmerⅠ试验、泪膜破裂时间、泪河宽度、血常规、肝肾功能等检查结果及治疗中的不良反应。

结果：两组患者的痊愈率、总显效率分别为(28.4% vs 13.5%)、(85.1% vs 70.3%)，差异具有统计学意义(χ²=12.255、6.547，均P<0.05)； 治疗前，两组患者SchirmerⅠ试验、泪膜破裂时间、泪河宽度检查结果差异无统计学意义(P>0.05)； 治疗后90d，研究组患者SchirmerⅠ试验、泪膜破裂时间、泪河宽度检查结果优于治疗前，差异具有统计学意义(均P<0.05)，及同期与对照组比较，差异具有统计学意义(均P<0.05)。

结论：二冬玉竹汤联合常规西医疗法治疗中青年睑板腺功能障碍所致干眼症安全有效。

METHODS:A total of 74 young and middle-aged yin deficiency and dryness heat patients(148 eyes)with xerophthalmia caused by meibomian gland dysfunction, who were visited at Ophthalmology Departments of our hospital and PLA 161^st Hospital between Feb. 2011 and Jan. 2015. They were assigned to the study group and the control group(each n=37, 74 eyes)in a randomized and average fashion. The latter received routine Western therapy, administration of artificial tears, while the former additionally received self-made Erdong Yuzhu Decoction(a traditional Chinese medicine)therapy on the same basis as the control group. Efficacy was evaluated and recorded were made regarding examination results, including pre- and posttreatment Schirmer Ⅰ tests(SⅠt), tear break-up time(BUT), width of lacrimal river, blood routine examination, and hepatic and renal function, and adverse reactions during treatment.

RESULTS: The cure rates and total response rates were 28.4% vs 13.5% and 85.1% vs 70.3% for patients in the study group and the control group, respectively(χ²=12.255, 6.547,P<0.05). Before treatment, patients in both groups showed comparable results of SⅠt, BUT and width of lacrimal river(P>0.05); 90d after treatment, the above three results in the study group were superior to those before treatment(P<0.05)and the homochromous control group(P<0.05). Patients enrolled had mild adverse actions.

CONCLUSION: It is a clinically considerable and propagable that Erdong Yuzhu Decoction plus routine Western therapy is a safe and effective integrated Chinese-Western therapy for xerophthalmia caused by meibomian gland dysfunction in the young and middle-aged.